Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of HLX208 in adults with BRAF V600E-mutated Langerhans cell histiocytosis or Erdheim-Chester disease
CTR20212459Phase 2Completed
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), sponsored by Suzhou Runxin Biotechnology. Started Jan 2022; status: completed.
02
Drugs
HLX208
03
Conditions
Langerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on CTR20212459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212459.